Dawn M Carlson
Overview
Explore the profile of Dawn M Carlson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
779
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kimball A, Okun M, Williams D, Gottlieb A, Papp K, Zouboulis C, et al.
N Engl J Med
. 2016 Aug;
375(5):422-34.
PMID: 27518661
Background: Hidradenitis suppurativa is a painful, chronic inflammatory skin disease with few options for effective treatment. In a phase 2 trial, adalimumab, an antibody against tumor necrosis factor α, showed...
2.
McKeegan E, Ansell P, Davis G, Chan S, Chandran R, Gawel S, et al.
Lung Cancer
. 2015 Oct;
90(2):296-301.
PMID: 26424209
Objectives: Linifanib, a potent and selective inhibitor of the tyrosine kinase activity of vascular endothelial growth factor and platelet-derived growth factor receptors, has clinical activity in advanced non-small cell lung...
3.
Ramalingam S, Shtivelband M, Soo R, Barrios C, Makhson A, Segalla J, et al.
J Clin Oncol
. 2015 Jan;
33(5):433-41.
PMID: 25559798
Purpose: Linifanib, a potent, selective inhibitor of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors, has single-agent activity in non-small-cell lung cancer (NSCLC). We evaluated linifanib with...
4.
Cainap C, Qin S, Huang W, Chung I, Pan H, Cheng Y, et al.
J Clin Oncol
. 2014 Dec;
33(2):172-9.
PMID: 25488963
Purpose: This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy. Patients And Methods: Patients were...
5.
ONeil B, Cainap C, Van Cutsem E, Gorbunova V, Karapetis C, Berlin J, et al.
Clin Colorectal Cancer
. 2014 Jul;
13(3):156-163.e2.
PMID: 25066269
Background: Although CRC is the third most commonly diagnosed cancer in the United States, second-line CRC treatment is limited. In this trial we examined the efficacy and safety of linifanib,...
6.
Horinouchi H, Yamamoto N, Nokihara H, Horai T, Nishio M, Ohyanagi F, et al.
Cancer Chemother Pharmacol
. 2014 May;
74(1):37-43.
PMID: 24807459
Introduction: Linifanib is a potent, orally active, and selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor kinase activities with clinical efficacy in non-small cell lung cancer...
7.
Davidson M, Rosenson R, Maki K, Nicholls S, Ballantyne C, Mazzone T, et al.
Arterioscler Thromb Vasc Biol
. 2014 Apr;
34(6):1298-306.
PMID: 24743431
Objective: To assess whether adding a fibrate to statin therapy reduces residual cardiovascular risk associated with elevated triglycerides and low high-density lipoprotein cholesterol, The Evaluation of Choline Fenofibrate (ABT-335) on...
8.
Chiu Y, LoRusso P, Hosmane B, Ricker J, Awni W, Carlson D
Cancer Chemother Pharmacol
. 2013 Nov;
73(1):213-7.
PMID: 24241212
Purpose: Linifanib is a selective inhibitor of the vascular endothelial growth factor and platelet-derived growth factor family of tyrosine kinase inhibitors. The purpose of this high-precision QT study was to...
9.
Chiu Y, Carlson D, Pradhan R, Ricker J
Clin Ther
. 2013 Oct;
35(11):1770-7.
PMID: 24094464
Background: Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths and the fifth most common cancer globally. Hepatocellular carcinoma produces highly vascular tumors that overexpress vascular endothelial...
10.
Weinstein D, Williams L, Carlson D, Kelly M, Burns K, Setze C, et al.
Clin Ther
. 2013 Jul;
35(8):1186-98.
PMID: 23891363
Background: Patients with chronic kidney disease (CKD) often have mixed dyslipidemia and high cardiovascular disease risk. Although statins reduce LDL-C, adding a fibrate may further improve lipid parameters. Objective: This...